Together with star investor Kleiner Perkins, Origenis GmbH, a privately held German biopharmaceutical company, successfully establishes its new business model for the clinical development of its neuroprotective drug pipeline. The formation and financing of Neuron23 Inc. was announced in South San Francisco.
Chemieanlagenbau Chemnitz (CAC) is realizing one of the first large-scale plants in Europe to use innovative co-processing to produce carbon-neutral fuels.
Kurma Parnters and Francee investment bank have launched a €50m project named Argobio that is aimed at identifiying the most genious biotech ideas and spin out companies.
British Oxular Ltd has raised $37m in a financing round led by Forbion Parners and co-financed by IP Group, NeoMed, and V-Bio Ventures to push its pipeline.